Clinical Trial Update: Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating albuvirtide in combination with 3BNC117 for multi-drug resistant HIV-1 infection (study status not yet disclosed).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Aids

Drugs mentioned

• 3BNC117
• albuvirtide (albuvirtide)

Snippet

Sponsor: Frontier Biotechnologies Inc. | Conditions: HIV/AIDS | Phase 2 | Status: UNKNOWN